MS
PROF

Maven Securities’s Profound Medical PROF Stock Holding History

Maven Securities’s Portfolio PROF Stock Details PROF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-50,000
Closed -$376K – 954
2024
Q4 		$376K Buy
+50,000
New +$384K 0.01% 652

Other funds holding PROF

Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.2B AUM 38.92% 1-Year Est. Return
TIM
Timelo Investment Management Aurora, Ontario, Canada $127M AUM 23.73% 1-Year Est. Return
GA
Gagnon Advisors New York $136M AUM 21.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Maven Securities's PROF Position: Q1 2025 in Review

Maven Securities sold out of Profound Medical (PROF) in Q1 2025, closing a stake of 50,000 shares — an estimated $376K sold.

Maven Securities first reported a position in PROF in Q4 2024 and held it in 1 quarter. The position peaked at $376K in Q4 2024. 49 funds tracked by Wall St. Rank hold PROF as of Q1 2025.

  • Maven Securities reported no remaining Profound Medical position as of Q1 2025 after selling out during the quarter.
  • Maven Securities sold 50,000 Profound Medical shares in Q1 2025, an estimated $376K.
  • Maven Securities first reported a position in Profound Medical in Q4 2024 and held it in 1 quarter.
  • Maven Securities's Profound Medical position peaked at $376K in Q4 2024.
  • 49 funds tracked by Wall St. Rank held Profound Medical as of Q1 2025.

Based on Maven Securities's 13F filing for Q1 2025, filed 14 May 2025.